Search

Search Constraints

You searched for: Author/Creator Middleton, Mark R.

Search Results

1. A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. Issue 1 (17th October 2018)

2. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria. (September 2022)

3. Assessment of the drug interaction potential and single‐ and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib. (30th December 2014)

4. Comment on 'Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines'. (May 2020)

5. Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines. (September 2019)

6. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Issue 14 (September 2015)

7. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Issue 14 (September 2015)

8. Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline. Issue 16 (November 2015)

9. Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma. (January 2020)

10. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention. (March 2020)